#129 - Tom Dayspring, M.D.: The latest insights into cardiovascular disease and lipidology

Mon, 21 Sep 2020 09:30:00 +0000

World-renowned lipidologist Tom Dayspring returns to give an update on the current thinking in lipidology as a follow-up to his 2018 five-part podcast series. In this episode, Tom discusses the growing consensus that atherogenic lipoproteins are essential drivers of atherosclerotic vascular disease. Tom further emphasizes apolipoprotein B (apoB) and lipoprotein(a) (Lp(a)). He provides insights into risk assessment, including which lab metrics to use, how to interpret them, and the appropriate therapeutic targets. Additionally, Tom discusses the most recent developments in lipid-lowering drug therapies—from the continued evolution of PCSK9 inhibitors, to the latest understanding of EPA and DHA, and the most recent addition of bempedoic acid to the list of therapeutic agents.

We discuss:

The latest in the field of lipidology and cardiovascular disease [3:45];

Apolipoproteins—the key to understanding lipid biology [9:30];

ApoB as a preferred metric over LDL-P [16:30];

Therapeutic goals for apoB concentration [21:45];

Drivers of atherosclerosis [34:15];

Overview and current thinking on high density lipoproteins (HDLs)—Is it a useful metric? [37:00];

Lipoprotein(a)—the most dangerous particle you’ve never heard of [55:00];

Are low density lipoprotein triglycerides (LDL-TGs) a useful metric? [1:13:15];

Tom’s preferred lab measurements [1:17:45];

The latest in lipid-lowering therapies [1:21:30];

The different pathways among various lipid-lowering drugs [1:30:45];

The latest on EPA and DHA [1:38:15];

Fibrates—an underappreciated treatment for hypercholesterolemia [1:49:45] and;

More.

Learn more: https://peterattiamd.com/

Show notes page for this episode: https://peterattiamd.com/tomdayspring6

Subscribe to receive exclusive subscriber-only content: https://peterattiamd.com/subscribe/

Sign up to receive Peter's email newsletter: https://peterattiamd.com/newsletter/

Connect with Peter on Faceboo k | Twitter | Instagram.